SCHEMBL334907

SCHEMBL334907

C[Sn](C)(C)c1cccc(C(=O)O)c1N1C(=O)CCC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA9 Q16790 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 5/20 0.34
ALOX15 P16050 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
RECQL P46063 1/20 0.34
KMT2A Q03164 4/20 0.34
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 1/20 0.33
GLA P06280 1/20 0.33
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL440026 0.80 ALDH1A1 (0.36) CA12CA1CA9ALDH1A1KDM4E
SCHEMBL317655 0.76 ALB (0.49) CA12CA1CA9ALDH1A1ALOX15
SCHEMBL4901236 0.73 TLR9 (0.49) CA12CA1CA9L3MBTL1ALDH1A1
SCHEMBL6006263 0.72 TSHR (0.56) L3MBTL1ALDH1A1KDM4EHPGDKMT2A
SCHEMBL4565322 0.70 ALDH1A1 (0.56) CA12CA1CA9ALDH1A1ALOX15
SCHEMBL28755352 0.70 TLR9 (0.45) CA12CA1CA9L3MBTL1ALDH1A1
SCHEMBL3678196 0.70 NPC1 (0.48) CA12CA1CA9ALDH1A1ALOX15
SCHEMBL9262225 0.68 GAA (0.55) CA12CA1CA9L3MBTL1ALDH1A1
SCHEMBL15636976 0.68 ALDH1A1 (0.43) CA12CA1CA9L3MBTL1ALDH1A1
SCHEMBL11564833 0.68 ALDH1A1 (0.43) CA12CA1CA9L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851383-B2 Automatic process platform for the production of astatine-211 [At-211]-radiopharmaceuticals ALPHA THERAPY SOLUTIONS AB (SE) 2023-12-26 US disclosed
US-20210139389-A1 AUTOMATIC PROCESS PLATFORM FOR THE PRODUCTION OF ASTATINE-211 [ AT 211] RADIOPHARMACEUTICALS ATLEY SOLUTIONS AB (SE) 2021-05-13 US disclosed
US-10829423-B2 Automatic process platform for the production of astatine-211 [At 211] radiopharmaceuticals ALPHA THERAPY SOLUTIONS AB (SE) 2020-11-10 US disclosed
EP-3157577-B1 AUTOMATIC PROCESS PLATFORM FOR THE PRODUCTION OF ASTATINE-211 [At-211]-RADIOPHARMACEUTICALS LINDEGREN STURE (SE) 2020-10-28 EP disclosed
US-20180215680-A1 AUTOMATIC PROCESS PLATFORM FOR THE PRODUCTION OF ASTATINE-211 [At-211]-RADIOPHARMACEUTICALS ATLEY SOLUTIONS AB (SE) 2018-08-02 US disclosed
EP-3334453-A2 ANTIBODY-BASED MOLECULES SPECIFIC FOR THE TRUNCATED ASP421 EPITOPE OF TAU AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY New York University (US) 2018-06-20 EP disclosed
EP-3166688-A1 TAU IMAGING LIGANDS AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY New York University (US) 2017-05-17 EP disclosed
EP-3157577-A1 AUTOMATIC PROCESS PLATFORM FOR THE PRODUCTION OF ASTATINE-211 [At-211]-RADIOPHARMACEUTICALS Lindegren, Sture (SE) 2017-04-26 EP disclosed
WO-2017027685-A2 ANTIBODY-BASED MOLECULES SPECIFIC FOR THE TRUNCATED ASP421 EPITOPE OF TAU AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY NEW YORK UNIVERSITY (US) 2017-02-16 WO disclosed
WO-2016007414-A1 TAU IMAGING LIGANDS AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY NEW YORK UNIVERSITY (US) 2016-01-14 WO disclosed
WO-2015195042-A1 AUTOMATIC PROCESS PLATFORM FOR THE PRODUCTION OF ASTATINE-211 [At-211]-RADIOPHARMACEUTICALS LINDEGREN STURE (SE) 2015-12-23 WO disclosed
US-8097254-B2 Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2012-01-17 US disclosed
US-20060133994-A1 Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis NERI DARIO 2006-06-22 US disclosed
EP-1259548-A1 ANTIBODY SPECIFIC FOR THE ED-B DOMAIN OF FIBRONECTIN, CONJUGATES COMPRISING SAID ANTIBODY, AND THEIR USE FOR THE DETECTION AND TREATMENT OF ANGIOGENESIS Eidgenössische Technische Hochschule Zürich (CH) 2002-11-27 EP disclosed
WO-2001062800-A1 ANTIBODY SPECIFIC FOR THE ED-B DOMAIN OF FIBRONECTIN, CONJUGATES COMPRISING SAID ANTIBODY, AND THEIR USE FOR THE DETECTION AND TREATMENT OF ANGIOGENESIS Eidgenössische Technische Hochschule Zürich (CH) 2001-08-30 WO disclosed